Although in the last few years a lot of studies have been published concerning the potential association of methylenetetrahydrofolate reductase (MTHFR) 677C > T polymorphism with the risk of FGR and placental abruption, they didn’t bring enough evidence to support introducing MTHFR genetic testing into routine clinical practice [76,77,78]. This evidence concerns the gene MTHFR and placental abruption.